Investigational Therapy BAN2401 Slows Alzheimer’s Progression Over 18 Months, Phase 2 Results Show

Investigational Therapy BAN2401 Slows Alzheimer’s Progression Over 18 Months, Phase 2 Results Show
Treatment with investigational compound BAN2401 over 18 months reduced the accumulation of amyloid fibers in the brain and slowed Alzheimer’s disease progression, according to top-line results from a Phase 2 trial. This follows a previous announcement in December 2017 by Eisai and Biogen, the therapy's developers, that the treatment had failed to promote significant changes after 12 months. After these initial disappointing results, an independent trial review committee declared the data was inconclusive, and researchers extended the trial for an additional six months. “The prospect of being able to offer meaningful disease-modifying therapies to individuals suffering from this terrible disease is both exciting and humbling,” Alfred Sandrock, MD, PhD, executive vice president and chief medical officer at Biogen, said in a press release. “These BAN2401 18-month data offer important insights in the investigation of potential treatment options for patients with Alzheimer’s disease and underscores that neurodegenerative diseases may not be as intractable as they once seemed.” BAN2401 is an engineered antibody that specifically binds and neutralizes toxic amyloid aggreg
Subscribe or to access all post and page content.